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Abstract
Radioiodine refractoriness is the main problem in the diagnosis and treatment of papillary thyroid carcinoma. The aim of the 
study was to investigate the cytological and immunocytochemical changes of thyrocytes in fine-needle aspiration smears of thyroid 
papillary cancer metastases in the course of the development of secondary radioiodine resistance. A total of 70 postoperative metas-
tases of thyroid papillary cancer (secondary radioiodine refractory metastases, previously responsive to radioiodine, that eventually 
loses the ability to radioiodine accumulation, radioiodine-avid metastases, primary radioiodine-refractory metastases), immuno-
histochemical staining of thyroid peroxidase, thyroglobulin, cytokeratin 17 and cytological analysis were performed. Revealing the 
presence of specific cellular phenotypes and structures in punctuates, a low percentage of thyroid peroxidase and thyroglobulin-pos-
itive thyrocytes allows the development of the method of cytological prediction of the radioiodine therapy effectiveness.
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1. Introduction 
As a result of the Chernobyl accident, there was a sharp increase in incidence of the thyroid 
cancer [1, 2]. For 20 years of observation, most cases of differentiated thyroid cancer (DTC) have 
shown the excellent prognosis for more than 95 % of patients thanks to thyroidectomy and radioio-
dine (RI) – therapy, based on the unique ability of the thyroid cells to accumulate RI [3, 4]. Despite 
the mainly auspicious prognosis of papillary thyroid carcinoma (PTC) without relapses in most 
cases even using the standard therapy (thyroidectomy, RI and suppressive therapy), metastases 
occur during the postoperative period in 2–29 % of cases [3]. 
Metastases which occur during the postoperative period can be of two types: radioiodine-av-
id (RIAM) (able to accumulate RI) and radioiodine refractory metastases (RIRM). RIRM develop 
in 5–20 % of cases, their cells lose their ability to RI accumulation, and RI therapy becomes in-
effective for them [5, 6]. A combination of studies appears to support the notion that survival for 
patients with RI-refractory DTC distant metastases is around 2.5–3.5 years [7, 8]. Early prediction 
of RI ability of metastatic DTC can be based on the cytological feature determination of thyrocytes 
in fine needle aspiration (FNA) smears of the RIRM. There are some ideas about the morphologi-
cal, immunohistochemical and molecular characteristics of RIRM [9, 10]. However, the cytological 
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studies of FNA smears in RIRM have not yet been conducted and accordingly no data have been 
obtained on the cytological characteristics of RIRM. 
The data regarding RI-refractoriness, classifies it as primary (the metastatic tissue does 
not ever concentrate RI), secondary (the metastatic tissue loses the ability to concentrate 
RI after previous evidence of RI-avid disease), and stable metastatic disease [4]. The study of 
changes of metastases’ thyrocytes’ characteristics, correlated with the loss of RI accumulation, 
presents scientific and practical interest. The results can be the basis for developing new meth-
ods for predicting and diagnosing radioiodine refractoriness. A suitable model for investigation of 
changes may be secondary radioiodine-refractory metastases (SRIRM). 
The study of antigens’ expression – thyroid peroxidase (TPO) and thyroglobulin (Tg) – 
which are involved in the process of RI accumulation and its retention with thyrocytes is of par-
ticular interest. We have previously shown that cytokeratin No. 17 (Ck17) is a cytological marker 
of the preoperative prognosis of RI resistance when determining its expression in FNA smears of 
primary PTC [11]. The thyrocytes that contains Ck17 are characterized by the weak expression of 
Tg, and TPO, which also makes it relevant to study the expression of Ck17 antigen in FNA smears 
of postoperative PTC metastases. 
The actual purpose of this work is to carry out cytological and immunocytochemical re-
searches of the thyrocyte population in FNA smears of PTC metastases that appear in the postoper-
ative period, and also to identify cytological changes that occur with the development of secondary 
radioiodine refractoriness in metastases. There is a unique opportunity to conduct a comparative 
cytological investigation of SRIRM on different stages of its existence (when metastases accumu-
late RI (STAGE_1) and when they lose this ability (STAGE_2)). 
2. Materials and methods of research 
2. 1. Patients 
Investigated groups included FNA smears of 70 PTC regional metastases in the neck which 
were found during the sonographic and scintigraphic examination after thyroidectomy and RI – 
therapy, i. e. in the postoperative period. The specimens were obtained from patients who were ex-
amined, diagnosed with the tumor and underwent to thyroid surgery and RI therapy in the Institute 
of Endocrinology and Metabolism (IEM). PTC metastases were identified by the neck sonography 
after treating patients with 100 mCi RI. All histopathological diagnoses were established according 
to the World Health Organisation (WHO) classification at the Laboratory of Morphology of Endo-
crine System of the IEM [12]. 4 patients had the histological diagnosis – folliculal variant of PTC 
(FVPC) in the group of RIAM. 3 patients had the histological diagnosis – diffuse-sclerosing vari-
ant of PTC (1-in group of RIAM, 1-in group of PRIRM, 1-in group of SRIRM). All other patients 
had the histological diagnosis – classical variant of PTC. The patients were both women (55) and 
man (15), with their age ranging from 27 to 61 years (average age 39.29±17.13). This study has been 
approved by the Ethics Committee of IEM (No. 28/1-KE of 16 June, 2014) and all patients have 
signed the written form consent. All procedures in this study strictly complied with the guidelines 
and principles of the Declaration of Helsinki, the Council of the Convention Europe on human 
rights and biomedicine, as well as relevant provisions of the WHO and the laws of Ukraine. 
We have analyzed FNA smears of 15 metastases, previously responsive to RI, that eventu-
ally loses the ability to RI accumulation (SRIRM), 25 metastases that were successfully treated, 
using RI therapy (RIAM) and 30 primary RI-refractory PTC metastases, which does not ever 
concentrate RI (PRIRM). The specimens were obtained from PTC regional metastases in the 
neck (paratraheal, jugular (cranial, medial, caudal), submandibular, supraclavicular metastatic 
lymph node), size from 4 to 33 mm. FNA of thyroid and metastases was performed under ultra-
sound guidance using a 21-gauge needle. Dried FNA smears were fixed for 5 minutes in methanol, 
followed by staining in Giemsa dye diluted in 0.067M phosphate buffer (pH 6.4) for 30 minutes. 
2. 2. Immunohistochemical staining
Immunocytochemistry (ICH) was performed on representative Giemsa-stained smears af-
ter they have been analyzed cytomorphologically which helps to unmask antigens [13]. We ap-
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plied indirect immunoperoxidase technique to identify certain antigens, using primary monoclonal 
mouse antibodies against Tg (DAK-Tg6, Dako, Denmark, 1:100 dilution,), TPO (TPO-47, Dako-
Cytomation, Denmark, 1:50 dilution), epithelial cell adhesion molecule (epCAM) (Ber-Ep4 Dako, 
Denmark, 1:100 dilution), Ck17 (E3, Dako, Denmark, 1:50 dilution). Polyclonal rabbit anti-mouse 
immunoglobulins/HRP (Dako, Denmark, 1:100 dilution) were applied as enzyme-labeled second-
ary antibodies. 3.3-diaminobenzidine tetrahydrochloride (Sigma, USA) was used as a chromogen. 
Endogenous peroxidase was inactivated by incubation in 1 % H2O2 in phosphate buffer (pH 7.4) 
at the room temperature for 30 minutes. Appropriate positive and negative controls for ICH were 
included. The expression of antigens was considered positive in the case cytoplasm of thyrocytes 
intensive staining. As a result approximately 1000 thyrocytes were counted at high magnification 
(×400) in each case. 
2. 3. Statistical analysis
Data were statistically processed using Statistica, version 11.0. When the p-value was <0.05, 
any differences were considered statistically significant. The Wilcoxon’s non-parametric test was 
applied to compare the expression of TPO, Tg, Ck17 between different stages of the existence of 
SRIRM (when they accumulate RI (STAGE_1) and when they lose this ability (STAGE_2) in the 
same patients. The Mann-Whitney U-test was applied to compare the expression of TPO, Tg, Ck17 
between PRIRM and RIAM. The chi-square test was used to compare frequencies of cytological 
signs (specific cellular phenotypes, structures, cystic degeneration) between PRIRM and RIAM 
and between different stages of the SRIRM. 
3. Results 
3. 1. Cytological features of PTC postoperative metastases 
A comparative cytologic study of thyrocytes’ population of postoperative PTC metas-
tases with different iodine accumulating ability was performed. From the point of view of 
cytology, when the metastases had the ability to accumulate RI (RIAM), they had the regular 
structure of cellular groups. These cellular groups were represented as homogeneous thy-
rocytes without signs of atypia (Fig. 1, a). In contrast, in a case of RI accumulation loss (in 
SRIRM and PRIRM) cellular groups with irregular structure appeared. They are represented 
as polymorphic cells. 
Some cellular phenotype, which differed from other cells of the thyrocyte population with 
cytomorphological and ICH characteristics in 40 % of STAGE_2 of SRIRM and 30 % PRIRM was 
found. Their positive antibody reaction to cytokeratins 7 and 8 instantiates an epithelial nature. 
These thyrocytes don’t contain Tg and do not react to antibodies against epCAM. This cellular 
phenotype looked lighter among the other epithelial cells and had clear-cut edges (Fig. 1, b). Sta-
tistically significant difference was observed in the presence of this specific cellular phenotype of 
thyrocytes between metastases of STAGE_1 and STAGE_2 of SRIRM.
a                                                      b
Fig. 1. Тhe cellular groups in FNA smears of postoperative PTC metastases:  
a – regular structure of cellular groups in RIAM;  
b – particular cellular phenotype in STAGE_2 of SRIRM. ×400 
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Besides, there are specific cellular complexes of psammous bodies and vacuolated cells in 
20 % of PRIRM and 46 % of STAGE_2 of SRIRM. These complexes were absent in metastases, 
when they had an ability to accumulate RI. (Fig. 2). 
Fig. 2. Specific cellular complexes of psammous bodies and vacuolated cells in FNA smear of 
STAGE_2 of SRIRM. ×400
Also, in 43 % of PRIRM and 40 % of cases of STAGE_2 of SRIRM there are cytological 
sign of cystic degeneration, in contrast to metastases, when they had an ability to accumulate RI. 
The data of the frequency of the studied cytological features in FNA smears of postoperative PTC 
metastases are given in Table 1. 
Table 1
The frequency of various cytological signs in FNA smears of postoperative PTC metastases (RIAM, PRIRM 
and SRIRM)
Cytological features RIAM (n=25)
PRIRM 
(n=30)
SRIRM (n=15)
Stage of RI accumulation 
(STAGE_1)
Stage of lost of RI accumulation 
(STAGE_2)
Special cellular phenotype 0 %# 30 % (9) 0 %* 40 % (6)
Cystic degeneration 4 % (1)# 43 % (13) 6.7 % (1)* 40 % (6)
Complexes of psammous 
body and thyrocytes 0 %# 20 % (6) 0 %* 46.6 % (7)
Note: RIAM – radioiodine-avid metastases, successfully treated using the radioiodine therapy, PRIRM – radioiodine-refractory 
metastases, which never accumulated radioiodine, SRIRM – which previously were responsive to radioiodine and eventually lose 
the ability to accumulate it; # – p<0.05 in comparison RIAM with PRIRM; * – p<0.05 in comparison STAGE_1 with the STAGE_2 
of SRIRM
So, conducted researches demonstrate appearance of the special cellular phenotype, com-
plexes of psammous body and thyrocytes and cystic degeneration in FNA smears of primary 
radioiodine-refractory metastases and the stage of lost radioiodine accumulation (STAGE_2) 
of SRIRM, compared to radioiodine-avid metastases and the stage of radioiodine-accumulation 
(STAGE_1) of SRIRM. 
3. 2. Immunocytochemical features of PTC postoperative metastases 
The statistically significant reduction of the expression of TPO and Tg at the level of sig-
nificance p<0.05 between RIAM and PRIRM was shown (p=0 and p=0.000028 respectively). 
The statistically significant reduction in the expression of TPO and Tg at the level of significance 
p<0.05 between different stages of the existence of SRIRM (STAGE_1 and STAGE_2) was shown 
(p=0.003346 for both antigens) (Fig. 3). However, in the smears of RIAM (which were success-
fully treated by RI), the percentage of TPO-positive thyrocytes reached 100 %. Whereas, in the 
FNA smears of STAGE_1 of SRIRM the percentage of TPO-positive cells was 15–75 % of thyro-
cytes. The difference between these groups of metastases in the expression of TPO was statisti-
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cally probable at the level of significance p<0.05 with the non-parametric Mann-Whitney U-test 
(p=0,000047). At the same time, after the loss of RI accumulation ability (STAGE_2), the FNA 
smears of SRIRM had only 0–7 % of TPO-positive cells. 
a                                                        b
Fig. 3. Immunocytochemical reaction with antibody to thyroid peroxidase in FNA smears of 
postoperative PTC radioiodine accumulating metastases: a – intensive expression of thyroid 
peroxidase in punctate of RIAM; b – mosaic expression of thyroid peroxidase in punctate of 
STAGE_1 of SRIRM, ×200
A statistically significant difference between STAGE_2 and STAGE_1 of SRIRM and as 
well as between PRIRM and RIAM was not shown with the Ck17-positive cells percentage at the 
level of significance p<0.05 (p=0.108810, p=0.910258). 
The data of the frequency of the studied imunocytochemical features in FNA smears of 
postoperative PTC metastases are given in Table 2. 
Table 2
The Median values (Me, %) of thyrocytes’ percentage with antigens’ expression (TPO, Tg, cK17) in FNA 
smears of postoperative PTC metastases (RIAM, PRIRM, SRIRM)
Imunocytochemacal features RIAM (n=25)
PRIRM 
(n=30)
SRIRM (n=15)
Stage of RI accumulation 
(STAGE_1)
Stage of lost of RI  
accumulation (STAGE_2)
TPO-positive cells (Me, %) 77.5 %# 0 % 20 %* 0 %
Tg-positive cells (Me, %) 92.5 %# 56 % 90 %* 50 %
Ck17-positive cells (Me, %) 0 % 0 % 0 %* 10 %
Note: RIAM – radioiodine-avid metastases, successfully treated using the radioiodine therapy, PRIRM – radioiodine-refrac-
tory metastases, which never accumulate radioiodine, SRIRM – which previously were responsive to radioiodine and eventu-
ally lose the ability to accumulate it; # – p<0.05 in comparison RIAM with RIRM; * – p<0.05 in comparison STAGE_1 with 
STAGE_2 of SRIRM 
So, the statistically significant difference of the expression of thyroid peroxidase and 
thyroglobulin between radioiodine accumulating metastases and primary radioiodine-refractory 
metastases, and between different stages of the existence of secondary radioiodine-refractory 
metastases (STAGE_1 and STAGE_2) was shown. Moreover, the different efficacy of radioio-
dine-therapy depending on thyroid peroxidase-positive cells percentage in FNA smears of me-
tastases was demonstrated.
4. Discussion
The study of FNA smears of postoperative PTC metastases with different iodine accu-
mulating ability revealed cytological changes and changes of some antigens’ expression that 
occurred in the thyrocyte’ population in course of the loss of RI-accumulation ability. The 
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conducted researches demonstrate the appearance of special cellular phenotypes and complex-
es in FNA smears of PRIRM and STAGE_2 of SRIRM, compared to RIAM and STAGE_1 of 
SRIRM. There is an emergence of some specific cellular phenotype that have no expression 
of Tg (marker of differentiated thyrocytes), which is relevant to the accumulation of RI during 
the loss of the ability to RI accumulation. The special cellular phenotype does not react with 
anti-epCAM (Ber EP4 antigen) antibodies. This is somewhat unexpected because epCAM, con-
sisting of two glycoproteins, 34 and 39 kDa, is found on the cell surface and in the cytoplasm of 
virtually all epithelial cells, with very few exceptions. In particular, epCAM expression is typi-
cal of follicular (A-cells), Hurthle (B-cells) and parafollicular (C-cells) cells of the thyroid, both 
in health and cancer [14]. EpCAM – adhesion molecules of epithelial cells, they also considered 
to be one of the key factors in the process of epithelial-mesenchymal transition, when epithelial 
cells lose their polarity and intercellular adhesion and acquire the ability to migration. Probably, 
these characteristics of specific cellular phenotype in explored metastases are a source of RI 
refractoriness. 
Also, there are specific cellular complexes of psammoma bodies and vacuolated thyrocytes 
in PRIRM and STAGE_2 of SRIRM that were absent in RI-accumulation metastases. Cytopatholo-
gists describe the numerous psammoma bodies in the single tissue fragment in a FNA smears from 
a diffuse sclerosing variant of PTC [15]. This variant of PTC is recognized as aggressive variants 
by the WHO. Probably, we can consider these complexes as a cytopathological sign of thyroid car-
cinoma’ aggression and RI-refractoriness. However, this assumption requires further investigation. 
The data regarding the tumors’ resistance to the commonly used therapy has shown that the 
clonal tumor heterogeneity may be based on its development [16]. Previously there was a demon-
stration of the population heterogeneity in follicular epithelium only on the histological sections of 
the thyroid nodule’s tissue [17]. We were the first to conduct the study of the tumor heterogeneity 
in the FNA smears of PTC metastases. 
There is a statistically significant reduction of PRIRM, compared to RIAM and of STAGE_2, 
compared to STAGE_1 of SRIRM in the expression of TPO and Tg, which is momentous in the 
accumulation and retention of RI by cells of follicular epithelium. The received results do not con-
tradict the literature data where researcher’s ICH investigations of the RIRM showed a significant 
reduction in their tissue Tg, TPO, and their mRNA [18, 19]. However, studies of these antigens’ 
expression in FNA smears of metastases during the development of secondary radioiodine re-
fractoriness were first conducted in this work. The appearance of special cellular phenotypes and 
complexes, the loss of antigens which take part in the accumulation and RI retention (TPO, Tg) may 
be a manifestation of the loss of cytological signs of high differentiation of thyrocytes that cause 
successful RI treatment. These data do not contradict the previously obtained results in the study 
of the histological material of PTC and their metastases [20]. 
TPO-antigen is related to the accumulation of RI [21, 22]. We can see, that the median value 
of TPO-positive cells percentage for RIAM, successfully treated using the radioiodine therapy 
(Me=80 %), was statistically probably higher than for the group of STAGE_1 that eventually be-
came STAGE_2 of SRIRM (Me=20 %). It demonstrated different efficacy of RI therapy, depending 
on TPO-positive cells percentage in FNA smears of metastases. We can see that the loss of the 
ability to RI accumulation of metastases happens despite the initial moderate ability during the 
development of secondary radioiodine refractoriness. Therefore, probably the low percentage of 
TPO-positive cells (up to 15 %), observable in FNA smears of STAGE_1 of SRIRM, may be not 
enough for the successful RI therapy. Basically, the reason of this phenomenon can be behind the 
phenotypic heterogeneity of tumors. Apparently, thyrocytes that have TPO and Tg are able to accu-
mulate RI and eventually are destroyed by this radiopharmaceutical means. And the development 
of secondary radioiodine refractoriness in metastases happens thanks to thyrocytes that do not 
contain TPO and Tg and are not able to RI accumulation.
5. Conclusions
The postoperative secondary radioiodine-refractory metastases of papillary thyroid car-
cinomas, which initially accumulated radioiodine (STAGE_1), but eventually lost this ability 
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(STAGE_2) were chosen as modeling for the study of cytological and immunocytochemical cells’ 
changes that occur in the dynamics of development of radioiodine refractoriness. 
The statistically significant reduction of the expression of thyroid peroxidase and thyro-
globulin between radioiodine accumulating metastases and primary radioiodine-refractory metas-
tases and between different stages of the existence of secondary radioiodine-refractory metastases 
(STAGE_1 and STAGE_2) was shown.
The conducted researches demonstrate the appearance of special cellular phenotypes and 
complexes in FNA smears of primary radioiodine-refractory metastases and the stage of lost ra-
dioiodine accumulation (STAGE_2) of secondary radioiodine-refractory metastases, compared to 
radioiodine-avid metastases, and the stage of radioiodine-accumulation (STAGE_1) of secondary 
radioiodine-refractory metastases.
The median value of thyroid peroxidase-positive cells percentage for radioiodine-avid me-
tastases, successfully treated, using the radioiodine therapy, was statistically probably higher than 
for the group of the radioiodine-accumulative stage of postoperative metastases (STAGE_1), which 
eventually became secondary radioiodine-refractory metastases. It demonstrated different effica-
cy of the radioiodine-therapy, depending on thyroid peroxidase-positive cells percentage in FNA 
smears of metastases.
Revealing the phenotypic heterogeneity of thyrocytes (presence of specific cellular pheno-
types, structures, cystic degeneration) in FNA smears and a low percentage of thyroid peroxidase and 
thyroglobulin-positive thyrocytes allows the development of the method of cytological prediction of 
the effectiveness of the radioiodine therapy of postoperative metastases of papillary thyroid cancer. 
Cytopathologists can use these results to provide their clinicians and patients with pertinent addition-
al diagnostic information, which could significantly impact patient management and outcome. 
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